Operaciones Olema Pharmaceuticals, Inc. - OLMA CFD
Agregar a Favoritos- Resumen
- Datos históricos
- Eventos
- Cuenta de resultados
- Balance de situación
- Flujo de caja
- Propiedad
Condiciones de trading
| Diferencial | 0.10 | ||||||||
|
Tarifa nocturna posición alcista
Long position overnight fee
Ir a la plataforma | -0.025457% | ||||||||
|
Tarifa nocturna posición bajista
Short position overnight fee
Ir a la plataforma | 0.003235% | ||||||||
| Horario tarifa nocturna | 21:00 (UTC) | ||||||||
| Cantidad comercializada mínima | 1 | ||||||||
| Divisa | USD | ||||||||
| Margen | 20% | ||||||||
| Mercado de valores | United States of America | ||||||||
| Comisión por operación | 0% |
*Information provided by Capital.com
Estadísticas clave
| Cierre previo* | 5.71 |
| Abrir* | 5.73 |
| Cambio de 1 año* | 106.86% |
| Rango del día* | 5.52 - 5.73 |
| Rango de 52 semanas | 2.19-7.45 |
| Volumen medio (10 días) | 196.85K |
| Volumen medio (3 meses) | 3.83M |
| Capitalización de mercado | 210.74M |
| Ratio P/E | -100.00K |
| Acciones en circulación | 40.76M |
| Ingresos | N/A |
| EPS | -2.74 |
| Dividendo (Rendimiento %) | N/A |
| Beta | -100.00K |
| Próxima fecha de resultados | Aug 7, 2023 |
"Todos los datos son proporcionados por Refinitiv, excepto los datos marcados con un asterisco, que son *datos proporcionados por Capital.com"
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Cierre | Change | Change (%) | Apertura | High | Low |
|---|---|---|---|---|---|---|
| Jun 1, 2023 | 5.71 | 0.58 | 11.31% | 5.13 | 5.77 | 5.13 |
| May 31, 2023 | 5.15 | 0.07 | 1.38% | 5.08 | 5.45 | 5.03 |
| May 30, 2023 | 5.35 | 0.16 | 3.08% | 5.19 | 5.38 | 4.98 |
| May 26, 2023 | 5.23 | -0.03 | -0.57% | 5.26 | 5.53 | 5.15 |
| May 25, 2023 | 5.37 | -0.05 | -0.92% | 5.42 | 5.47 | 5.18 |
| May 24, 2023 | 5.51 | 0.26 | 4.95% | 5.25 | 5.80 | 5.20 |
| May 23, 2023 | 5.51 | -0.64 | -10.41% | 6.15 | 6.40 | 5.15 |
| May 22, 2023 | 6.21 | -0.62 | -9.08% | 6.83 | 7.02 | 6.21 |
| May 19, 2023 | 6.82 | 0.26 | 3.96% | 6.56 | 7.22 | 6.56 |
| May 18, 2023 | 6.62 | -0.16 | -2.36% | 6.78 | 6.91 | 6.48 |
| May 17, 2023 | 6.90 | 0.70 | 11.29% | 6.20 | 7.22 | 6.17 |
| May 16, 2023 | 6.29 | -0.02 | -0.32% | 6.31 | 6.62 | 6.23 |
| May 15, 2023 | 6.64 | -0.34 | -4.87% | 6.98 | 7.03 | 6.24 |
| May 12, 2023 | 6.95 | 0.14 | 2.06% | 6.81 | 7.16 | 6.76 |
| May 11, 2023 | 6.78 | 0.35 | 5.44% | 6.43 | 7.09 | 6.43 |
| May 10, 2023 | 6.62 | -0.14 | -2.07% | 6.76 | 7.31 | 5.96 |
| May 9, 2023 | 7.26 | 1.03 | 16.53% | 6.23 | 7.37 | 6.22 |
| May 8, 2023 | 6.55 | 0.27 | 4.30% | 6.28 | 6.75 | 6.28 |
| May 5, 2023 | 6.64 | 0.06 | 0.91% | 6.58 | 6.83 | 6.33 |
| May 4, 2023 | 6.29 | 0.39 | 6.61% | 5.90 | 6.53 | 5.73 |
Olema Pharmaceuticals, Inc. Events
| Hora (UTC) (UTC) | País | Evento |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Hora (UTC) (UTC) 19:00 | País US
| Evento Olema Pharmaceuticals Inc at Jefferies Healthcare Conference Olema Pharmaceuticals Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Thursday, June 15, 2023 | ||
| Hora (UTC) (UTC) 15:00 | País US
| Evento Olema Pharmaceuticals Inc Annual Shareholders Meeting Olema Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Friday, June 16, 2023 | ||
| Hora (UTC) (UTC) 15:00 | País US
| Evento Olema Pharmaceuticals Inc Annual Shareholders Meeting Olema Pharmaceuticals Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Hora (UTC) (UTC) 20:00 | País US
| Evento Q2 2023 Olema Pharmaceuticals Inc Earnings Release Q2 2023 Olema Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Hora (UTC) (UTC) 21:30 | País US
| Evento Q3 2023 Olema Pharmaceuticals Inc Earnings Release Q3 2023 Olema Pharmaceuticals Inc Earnings ReleaseForecast -Previous - |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 106.988 | 71.491 | 21.528 | 4.323 | 2.173 |
| Gastos de venta/general/administración Gastos, total | 24.714 | 20.391 | 7.824 | 0.403 | 0.386 |
| Investigación y desarrollo | 82.274 | 51.1 | 13.704 | 3.92 | 1.693 |
| Gastos (ingresos) extraordinarios | 0 | 0.094 | |||
| Ingresos de explotación | -106.988 | -71.491 | -21.528 | -4.323 | -2.173 |
| Ingresos por intereses (gastos), netos No operativos | 2.228 | 0.442 | -0.593 | 0.007 | -0.024 |
| Otros, netos | -0.027 | -0.047 | 0 | 0 | |
| Ingresos netos antes de impuestos | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Ingresos netos después de impuestos | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Beneficio neto antes de partidas extra. Elementos | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Ingresos netos | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Total Adjustments to Net Income | 0 | -1.869 | 0 | 0 | |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -104.787 | -71.096 | -23.99 | -4.316 | -2.197 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -104.787 | -71.096 | -23.99 | -4.316 | -2.197 |
| Beneficio neto diluido | -104.787 | -71.096 | -23.99 | -4.316 | -2.197 |
| Promedio ponderado de acciones diluidas | 39.9955 | 39.5243 | 38.5197 | 38.5197 | 38.5197 |
| BPA diluido sin partidas extraordinarias | -2.61997 | -1.79879 | -0.6228 | -0.11205 | -0.05704 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
| BPA normalizado diluido | -2.61997 | -1.79879 | -0.6228 | -0.11205 | -0.0546 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Ingresos totales | 0 | 0 | 0 | 0 | 0 |
| Gastos totales de explotación | 29.602 | 27.219 | 23.222 | 33.293 | 23.254 |
| Gastos de venta/general/administración Gastos, total | 6.776 | 5.635 | 5.595 | 6.239 | 7.245 |
| Investigación y desarrollo | 22.826 | 21.584 | 17.627 | 27.054 | 16.009 |
| Ingresos de explotación | -29.602 | -27.219 | -23.222 | -33.293 | -23.254 |
| Ingresos por intereses (gastos), netos No operativos | 1.305 | 0.973 | 0.622 | 0.415 | 0.218 |
| Ingresos netos antes de impuestos | -28.286 | -26.179 | -22.72 | -32.858 | -23.03 |
| Ingresos netos después de impuestos | -28.286 | -26.179 | -22.72 | -32.858 | -23.03 |
| Beneficio neto antes de partidas extra. Elementos | -28.286 | -26.179 | -22.72 | -32.858 | -23.03 |
| Ingresos netos | -28.286 | -26.179 | -22.72 | -32.858 | -23.03 |
| Ingresos disponibles para los accionistas, excluyendo las partidas extra. Elementos | -28.286 | -26.179 | -22.72 | -32.858 | -23.03 |
| Ingresos disponibles para los accionistas, incluidos los elementos extra. Elementos | -28.286 | -26.179 | -22.72 | -32.858 | -23.03 |
| Beneficio neto diluido | -28.286 | -26.179 | -22.72 | -32.858 | -23.03 |
| Promedio ponderado de acciones diluidas | 40.3545 | 40.1906 | 40.0362 | 39.9182 | 39.8346 |
| BPA diluido sin partidas extraordinarias | -0.70094 | -0.65137 | -0.56749 | -0.82313 | -0.57814 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| BPA normalizado diluido | -0.70094 | -0.65137 | -0.56749 | -0.82313 | -0.57814 |
| Otros, netos | 0.011 | 0.067 | -0.12 | 0.02 | 0.006 |
| Total Adjustments to Net Income |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 208.899 | 290.685 | 342.137 | 0.103 | 3.242 |
| Efectivo e inversiones a corto plazo | 204.421 | 287.25 | 338.549 | 0.068 | 3.149 |
| Efectivo y Equivalentes | 23.702 | 13.812 | 338.549 | 0.068 | 3.149 |
| Prepaid Expenses | 2.655 | 3.212 | 3.439 | 0 | 0 |
| Other Current Assets, Total | 1.504 | 0.223 | 0.149 | 0.035 | 0.093 |
| Total Assets | 215.645 | 295.945 | 342.722 | 0.132 | 3.271 |
| Property/Plant/Equipment, Total - Net | 3.975 | 4.72 | 0.075 | 0.026 | 0.026 |
| Property/Plant/Equipment, Total - Gross | 4.556 | 4.944 | 0.106 | 0.097 | |
| Accumulated Depreciation, Total | -0.581 | -0.224 | -0.08 | -0.071 | |
| Other Long Term Assets, Total | 2.771 | 0.54 | 0.51 | 0.003 | 0.003 |
| Total Current Liabilities | 16.549 | 9.019 | 4.585 | 1.378 | 0.201 |
| Accounts Payable | 0.374 | 0.023 | 0.719 | 0.935 | 0.116 |
| Accrued Expenses | 16.025 | 8.53 | 3.494 | 0 | 0 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.15 | 0.466 | 0.372 | 0.443 | 0.085 |
| Total Liabilities | 18.099 | 11.377 | 4.585 | 1.378 | 0.201 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 197.546 | 284.568 | 338.137 | -1.246 | 3.07 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 9.348 | 9.348 |
| Common Stock | 0.003 | 0.003 | 0.003 | 0 | 0 |
| Additional Paid-In Capital | 408.333 | 388.904 | 371.228 | 0.168 | 0.168 |
| Retained Earnings (Accumulated Deficit) | -208.977 | -104.19 | -33.094 | -10.762 | -6.446 |
| Total Liabilities & Shareholders’ Equity | 215.645 | 295.945 | 342.722 | 0.132 | 3.271 |
| Total Common Shares Outstanding | 40.2871 | 39.7973 | 39.3082 | 38.5197 | 38.5197 |
| Inversiones a corto plazo | 180.719 | 273.438 | |||
| Other Liabilities, Total | 1.55 | 2.358 | |||
| Other Equity, Total | -1.813 | -0.149 | |||
| Total deudores, neto | 0.319 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Activo Corriente | 189.397 | 208.899 | 225.058 | 243.026 | 270.214 |
| Efectivo e inversiones a corto plazo | 185.954 | 204.421 | 222.6 | 240.711 | 267.867 |
| Efectivo y Equivalentes | 40.918 | 23.702 | 26.804 | 24.526 | 21.509 |
| Inversiones a corto plazo | 145.036 | 180.719 | 195.796 | 216.185 | 246.358 |
| Prepaid Expenses | 3.069 | 2.655 | 1.298 | 1.348 | 2.23 |
| Other Current Assets, Total | 0.072 | 1.504 | 1.16 | 0.967 | 0.117 |
| Total Assets | 195.768 | 215.645 | 231.997 | 250.6 | 277.418 |
| Property/Plant/Equipment, Total - Net | 3.6 | 3.975 | 4.168 | 4.478 | 4.41 |
| Property/Plant/Equipment, Total - Gross | 4.281 | 4.556 | 4.652 | 4.871 | 4.718 |
| Accumulated Depreciation, Total | -0.681 | -0.581 | -0.484 | -0.393 | -0.308 |
| Other Long Term Assets, Total | 2.771 | 2.771 | 2.771 | 3.096 | 2.794 |
| Total Current Liabilities | 19.41 | 16.549 | 12.552 | 12.308 | 10.168 |
| Accounts Payable | 0.681 | 0.374 | 0.014 | 0.12 | 0.268 |
| Accrued Expenses | 18.569 | 16.025 | 12.278 | 11.757 | 9.51 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.16 | 0.15 | 0.26 | 0.431 | 0.39 |
| Total Liabilities | 20.793 | 18.099 | 14.298 | 14.317 | 12.328 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 174.975 | 197.546 | 217.699 | 236.283 | 265.09 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | |
| Common Stock | 0.003 | 0.003 | 0.003 | 0.003 | 0.003 |
| Additional Paid-In Capital | 413.213 | 408.333 | 403.168 | 398.756 | 393.933 |
| Retained Earnings (Accumulated Deficit) | -237.263 | -208.977 | -182.798 | -160.078 | -127.22 |
| Other Equity, Total | -0.978 | -1.813 | -2.674 | -2.398 | -1.626 |
| Total Liabilities & Shareholders’ Equity | 195.768 | 215.645 | 231.997 | 250.6 | 277.418 |
| Total Common Shares Outstanding | 40.4383 | 40.2871 | 40.0846 | 39.9745 | 39.8693 |
| Other Liabilities, Total | 1.383 | 1.55 | 1.746 | 2.009 | 2.16 |
| Total deudores, neto | 0.302 | 0.319 |
- Anual
- Trimestral
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Ingresos netos/Línea de salida | -104.787 | -71.096 | -22.121 | -4.316 | -2.197 |
| Efectivo de actividades de explotación | -82.065 | -50.69 | -19.866 | -3.081 | -2.176 |
| Efectivo de actividades de explotación | 0.357 | 0.163 | 0.011 | 0.009 | 0.008 |
| Partidas no monetarias | 19.343 | 17.413 | 3.749 | 0 | 0.123 |
| Cambios en el capital circulante | 3.022 | 2.83 | -1.505 | 1.226 | -0.11 |
| Efectivo de actividades de inversión | 91.479 | -275.438 | -0.056 | 0 | 0 |
| Gastos de capital | -0.363 | -1.575 | -0.056 | 0 | 0 |
| Efectivo procedente de actividades de financiación | 0.476 | 1.391 | 358.403 | 0 | 5.254 |
| Elementos de flujo de caja de financiación | 0 | 0 | |||
| Emisión (retiro) de acciones, neto | 0.476 | 1.391 | 355.315 | 0 | 4.931 |
| Emisión (amortización) de deuda, neta | 0 | 3.088 | 0 | 0.323 | |
| Variación neta de la tesorería | 9.89 | -324.737 | 338.481 | -3.081 | 3.078 |
| Otras partidas de flujo de caja de inversión, total | 91.842 | -273.863 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -28.286 | -104.787 | -78.608 | -55.888 | -23.03 |
| Cash From Operating Activities | -20.391 | -82.065 | -62.354 | -44.362 | -17.903 |
| Cash From Operating Activities | 0.1 | 0.357 | 0.26 | 0.169 | 0.084 |
| Non-Cash Items | 4.088 | 19.343 | 14.727 | 10.315 | 5.294 |
| Changes in Working Capital | 3.707 | 3.022 | 1.267 | 1.042 | -0.251 |
| Cash From Investing Activities | 37.387 | 91.479 | 75.143 | 54.979 | 25.567 |
| Capital Expenditures | 0 | -0.363 | -0.19 | -0.051 | -0.03 |
| Other Investing Cash Flow Items, Total | 37.387 | 91.842 | 75.333 | 55.03 | 25.597 |
| Net Change in Cash | 17.216 | 9.89 | 12.992 | 10.714 | 7.697 |
| Cash From Financing Activities | 0.22 | 0.476 | 0.203 | 0.097 | 0.033 |
| Issuance (Retirement) of Stock, Net | 0.22 | 0.476 | 0.203 | 0.097 | 0.033 |
| Financing Cash Flow Items | |||||
| Issuance (Retirement) of Debt, Net |
| Nombre del Inversor | Tipo de inversor | Porcentaje pendiente | Acciones en propiedad | Cambio de acciones | Fechas de holding | Índice de rotación |
|---|---|---|---|---|---|---|
| BVF Partners L.P. | Hedge Fund | 18.6732 | 7611503 | 0 | 2023-03-31 | LOW |
| Logos Global Management LLC | Investment Advisor | 9.2214 | 3758818 | 14943 | 2023-04-25 | LOW |
| Cormorant Asset Management, LP | Hedge Fund | 7.561 | 3082000 | 1000000 | 2023-03-31 | LOW |
| Paradigm BioCapital Advisors LP | Investment Advisor | 6.1703 | 2515111 | 132734 | 2023-04-10 | |
| Janus Henderson Investors | Investment Advisor/Hedge Fund | 5.1155 | 2085179 | -972127 | 2023-03-31 | LOW |
| Kynam Capital Management LP | Hedge Fund | 4.9356 | 2011853 | -13381 | 2023-03-31 | HIGH |
| Vivo Capital, LLC | Venture Capital | 4.1449 | 1689515 | 0 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 3.699 | 1507767 | 32417 | 2023-03-31 | LOW |
| Citadel Advisors LLC | Hedge Fund | 3.0188 | 1230516 | 5366 | 2023-03-31 | HIGH |
| Harmon (Cyrus) | Individual Investor | 2.8967 | 1180742 | 7568 | 2023-04-25 | |
| Sectoral Asset Management Inc. | Investment Advisor/Hedge Fund | 2.4432 | 995909 | -445896 | 2023-03-31 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.6387 | 667979 | -39756 | 2023-03-31 | LOW |
| Myles (David C Ph.D.) | Individual Investor | 1.4274 | 581821 | -10000 | 2021-12-10 | |
| Acadian Asset Management LLC | Investment Advisor/Hedge Fund | 1.4128 | 575900 | 0 | 2023-03-31 | MED |
| Laurion Capital Management LP | Hedge Fund | 1.2609 | 513972 | 18672 | 2023-03-31 | HIGH |
| Rappaport (Andrew) | Individual Investor | 1.1801 | 481014 | 0 | 2023-04-25 | |
| J. Goldman & Co., L.P. | Hedge Fund | 1.0968 | 447083 | -68494 | 2023-03-31 | HIGH |
| Adage Capital Management, L.P. | Hedge Fund | 1.0304 | 420000 | 0 | 2023-03-31 | LOW |
| Kovacs Shane William Charles | Individual Investor | 0.972 | 396197 | 15000 | 2023-04-25 | |
| Newtyn Management, LLC | Hedge Fund | 0.92 | 375000 | 15000 | 2023-03-31 | MED |
¿Por qué operar con Capital.com? Nuestros números hablan por nosotros
Capital.com Group535K+
Traders
87K+
Clientes activos mensualmente
$113M+
Volumen mensual de inversión
$64M+
Retiros por mes
Calculadora de trading
Calcula tus P&L hipotéticas en el supuesto de haber abierto una operación con CFD en una fecha determinada (selecciona una fecha) y haberla cerrado en otra fecha (selecciona una fecha).
Comisión de la operación
0
- 1:1
Apalancamiento
1:1
- 20
- 100
- 500
- 1000
- 10000
Inversión
Tamaño de la operación (Apalancamiento x Inversión)
Apertura
Cierre
En corto En largo
Olema Pharmaceuticals, Inc. Company profile
Sobre Olema Pharmaceuticals Inc
Olema Pharmaceuticals, Inc. es una empresa biofarmacéutica en fase clínica. La empresa se centra en el descubrimiento, el desarrollo y la comercialización de terapias dirigidas al cáncer femenino. Su principal candidato a producto, el OP-1250, es una terapia oral con actividad combinada como antagonista completo de los receptores de estrógenos (CERAN) y degradador selectivo de los mismos (SERD). OP-1250 es una pequeña molécula oral candidata a producto en fase clínica para el tratamiento de cánceres de origen endocrino. Se diseñó a partir de un conocimiento estructural del RE. OP-1250, tanto en monoterapia como en combinación con inhibidores de la quinasa dependiente de ciclina cuatro y seis (CDK4/6), demostró una sólida reducción del tumor en varios modelos de xenoinjerto, incluido un modelo de metástasis cerebral de cáncer de mama. Está en curso un ensayo clínico de fase 1/2, y en combinación de fase 1b con palbociclib, en pacientes con cáncer de mama metastásico de tipo ER-positivo (ER+), receptor del factor de crecimiento epidérmico humano 2-negativo (HER2-).
El precio actual de la acción Olema Pharmaceuticals, Inc. en tiempo real es 5.57 USD. El gráfico de la acción permite a los inversores comprender mejor el rendimiento y el precio de la acción y tomar decisiones informadas al negociar acciones y CFD.
Descubra más acciones con gráficos, datos vitales y actualizaciones de precios en tiempo real: Capstar Financial, Momentus Inc., Manulife Financial, iShares Short Treasury Bond ETF, Subaru Corporation y Lazydays. Para obtener más información, consulte los perfiles de las empresas en Capital.com.
| Industry: | Biotechnology & Medical Research (NEC) |
512 2Nd Street, 4Th Floor
Suite 250
SAN FRANCISCO
CALIFORNIA 94107
US
Cuenta de resultados
- Annual
- Quarterly
A la gente también le interesa
¿Aún estás buscando un bróker de confianza?
Únete a más de 535.000 traders de todo el mundo que eligen operar con Capital.com